GSK 3862995
Alternative Names: GSK-3862995Latest Information Update: 11 Mar 2024
At a glance
- Originator GSK
- Class Antibodies
- Mechanism of Action Immunomodulators; Interleukin-33 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 27 Nov 2023 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (unspecified route) (NCT06154837) (GSK pipeline, February 2024)